Search
Zalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnA dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.
Rifampin
go.drugbank.com/drugs/DB01045ApprovedInvestigational[A263768] Rifampin is used to treat tuberculosis and works by inhibiting the microbial DNA-dependent RNA polymerase (RNAP).[A263768]
Synonyms: 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetateOmega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawn[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … The rest of the concentration is represented by docosapentaenoic acid and traces of some other components such as alpha-tocopherol, gelatin, glycerol, sorbitol and purified water.
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnIt was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962.
Naloxone
go.drugbank.com/drugs/DB01183ApprovedInvestigationalVet approvedFrequently also carried by medical and emergency personnel and at events known to be associated with heavy drug use like music festivals, naloxone kits are considered a key component of harm reduction … Notably, if injected into a person not currently using opioid medications, there would be no noticeable effects at all.
Mixtures: TALWIN Nx, VALORON NSynonyms: 1-N-Allyl-14-hydroxynordihydromorphinoneBerahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalThis combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications … Berahyaluronidase alfa is a recombinant variant of human hyaluronidase designed to enhance dispersion and permeation of subcutaneously co-administered drugs.
Cilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigationalThe first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. … Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism.
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigational[A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061] … Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth
Aminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnAn aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.
Elosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)